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Abstract 
Background: Uterine sarcoma is an aggressive malignancy with a poor prognosis. This study aimed to determine the 
expression of CD146, P53, and Ki‑67 in uterine sarcoma and to evaluate their prognostic significance.
Methods: We retrospectively analyzed the prognosis and clinicopathologic features of 68 patients with uterine 
sarcoma. Immunohistochemical analyses of CD146, P53, and Ki‑67 were performed in tissue samples collected from 
these patients and their relationship with prognosis was investigated.
Results: The 5‑year overall survival (OS) rate was 46 %. Endometrial stromal sarcoma (ESS) patients had a better prog‑
nosis than leiomyosarcoma (LMS) patients, with a 2‑year survival rate of 82 %. The membrane and cytoplasm of tumor 
cells exhibited CD146 overexpression in 8 (32 %) ESS cases, which was less than the 25 (69.4 %) cases observed in LMS 
and 2 (28.6 %) in MMMT. CD146 overexpression in the membrane and cytoplasm of tumor cells was closely related 
to lymph node metastasis (P = 0.021) and Ki‑67 overexpression (P = 0.0053); there was no significant correlation with 
age, tumor size, International Federation of Obstetrics and Gynecology stage, or P53 overexpression in LMS.
Conclusions: CD146, P53, and Ki‑67 are overexpressed in uterine sarcoma. CD146 expression correlates with lymph 
node metastasis and is associated with poor OS in LMS; it may be a potential prognostic marker for LMS.
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Background
Uterine sarcoma, a rare and heterogeneous malignant 
tumor, accounts for only 3 % of all uterine malignancies 
[1]; the annual incidence is <2 per 100,000 women [2]. 
According to the World Health Organization (WHO) 
2003 classification system, there are three main uterine 
sarcoma subtypes: leiomyosarcoma (LMS), endometrial 
stromal sarcoma (ESS), and undifferentiated sarcoma 
(UD) [3]. Carcinosarcoma (malignant mixed Müllerian 
tumor, MMMT) is an undifferentiated sarcoma that was 
excluded as a uterine sarcoma in the 2009 National Com-
prehensive Cancer Network guidelines; however, most 
retrospective studies still include MMMT as a uterine 
sarcoma [4]. The prognostic factors of uterine sarcoma 
are not well established, with no consensus on their 
significance.
P53 gene mutations occur in approximately one-half 
of all tumors in a wide range of human malignancies and 
overexpression is associated with poor prognosis [5]. 
There are several reports of P53 overexpression in uter-
ine LMS, MMMT, and ESS [6, 7]. Ki-67 expression is also 
associated with poor prognosis in uterine sarcoma [8]. 
During the last decade, several studies were performed to 
assess estrogen receptor, progesterone receptor, P53, and 
Ki-67 expression as prognostic factors in LMS [9].
CD146, an adhesion molecule belonging to the immu-
noglobulin superfamily, was first identified as a mela-
noma-specific cell adhesion molecule [10]. CD146 is 
overexpressed in cancers such as epithelial ovarian can-
cer and breast cancer, in addition to melanoma [11, 12]. 
A recent study suggested that CD146 might be involved 
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in tumor development and be associated with prognosis 
in several systemic tumors [13].
Previous studies have shown that CD146 is a tumor 
angiogenesis marker. Zhang et  al. reported that CD146 
is present in most blood vessels in cervical and endome-
trial cancer, suggesting that it may be actively involved in 
cervical and endometrial cancer metastasis via the vas-
cular system [14]. The anti-CD146 monoclonal antibody 
AA98 inhibits angiogenesis and tumor growth. AA98 
has antiangiogenic properties in vitro and in vivo. AA98 
inhibits human umbilical vein endothelial cell prolif-
eration and migration as well as angiogenesis, validating 
CD146 as a novel target for antiangiogenic agents [15]. 
Wen et  al. found that CD146 expression promoted epi-
thelial–mesenchymal transition, correlating with mesen-
chymal marker expression and indicating poor prognosis 
in gastric cancer. CD146 downregulation induced down-
regulation of the genes for vimentin, fibronectin, and 
thrombospondin, which are mesenchymal markers [16].
However, no study to date has reported on CD146 
expression in uterine sarcoma. In the present study, 
we compiled data from patients diagnosed with uter-
ine sarcoma from the Sun Yat-Sen University Cancer 
Center (SYSUCC) in Guangzhou, China to investigate 
associations between the expression of CD146, the cell 
proliferation molecule Ki-67, and P53 and the patients’ 
clinicopathologic features and prognosis.
Methods
Patient selection and treatment
This retrospective study involved 68 patients diagnosed 
with primary uterine sarcoma who underwent surgical 
treatment from January 1996 to December 2011 at SYS-
UCC. Paraffin-embedded (PE) tissue samples were col-
lected from the pathology department as stored specimens. 
Prior consent from patients was obtained for research use 
of their PE tissues. This study was approved by the SYS-
UCC Institutional Review Board. We agreed to provide 
copies of the appropriate documentation if requested.
Patients were examined at 2-month intervals for the 
first 2 years, at 6-month intervals for the next 3 years, and 
once per year thereafter. The median follow-up period 
was 63.3  months (range 1–272.1  months). The primary 
end point was any cancer-related death. To ensure diag-
nostic accuracy, experienced pathologists conducted the 
pathologic diagnoses. Clinical data were retrieved from 
medical records in the institutional database. The follow-
up data were updated in August 2013.
The patients were selected using the following crite-
ria: diagnosed with uterine sarcoma according to the 
2003 WHO diagnostic criteria; no preoperative antitu-
mor treatment; no previous malignant disease or sec-
ond primary tumor; and complete clinicopathologic and 
follow-up data available. Patients who met these criteria 
were included.
The patients’ clinicopathologic characteristics were: age 
at diagnosis; International Federation of Obstetrics and 
Gynecology (FIGO) stage; histopathologic subtype; sur-
gical procedure; postoperative adjuvant therapy; pelvic 
lymphadenectomy; lymph node involvement; tumor size; 
distant metastasis and recurrence; and CD146, P53, and 
Ki-67 immunohistochemical staining patterns.
The standard surgical treatment for ESS and LMS was 
total abdominal hysterectomy (TAH) plus bilateral sal-
pingo-oophorectomy (BSO); pelvic lymphadenectomy 
(PL) was performed for late-stage patients (stage III/
IV). Para-aortic lymph node dissection was performed 
for patients with suspected common iliac or para-aortic 
lymph node involvement. Omentectomy was performed 
for stage III/IV patients. Adjuvant radiotherapy and/
or adjuvant chemotherapy was administered to patients 
with the following pathologic risk factors: incomplete 
resection in late-stage cases; positive pelvic lymph nodes; 
vascular and lymphatic permeation; high-grade ESS; 
tumor size >5  cm; and mitotic index (MI) >10/high-
power field (HPF). Radiotherapy comprised external 
pelvic irradiation (18  MV X-rays) using the multiport 
technique. Daily fractions of 1.8–2.0  Gy were adminis-
tered over 5–6 weeks for a total dose of 50 Gy. Chemo-
therapy mainly comprised cisplatin (60–75  mg/m2, d1) 
plus adriamycin (40–50  mg/m2, d1) plus dacarbazine 
(200 mg/m2, d1–5) as the primary drugs and was admin-
istered in three to five courses over a 3-week period.
The surgical treatment for MMMT usually comprised 
TAH plus BSO, PL, and omentectomy. We administered 
radiotherapy and chemotherapy for all MMMT cases.
Immunohistochemistry
Formalin-fixed and PE tumor tissue samples were used 
for immunohistochemical analysis. Sections (4 μm thick) 
containing the area of the tumor with the highest grade of 
atypia and the least necrosis were obtained from the paraf-
fin block, mounted on slides, and deparaffinized in xylene, 
ethanol, and distilled water. Following 10-min incubation 
with 3 % hydrogen peroxide in methanol, the slides were 
boiled in citrate buffer solution (pH 6) for 10  min using 
a domestic pressure cooker. The sections were incubated 
overnight at 4  °C with P53, P27, Ki-67, and CD146 anti-
bodies (1:100; Zhongshan Golden Bridge Biotechnol-
ogy, Beijing, China). Then, the slides were washed with 
phosphate-buffered saline and incubated for 30  min at 
37  °C with biotinylated goat antimouse secondary anti-
body (1:25; Lab Vision, Fremont, CA, USA). All slides were 
stained with 3,3′-diaminobenzidine and scored for immu-
noreactivity based on the percentage of positive tumor 
cells (percent positivity) and staining intensity (weak, 
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moderate, strong). Slides with scores of (−) or (+) were 
deemed negative; slides with scores of (++) or (+++) 
were deemed positive. Two experienced pathologists con-
firmed the results in a double-blind analysis [12].
Statistical analysis
Statistical analyses were performed using SPSS v16.0 
software (IBM, Armonk, NY, USA). Prognosis was 
determined based on overall survival (OS) and disease-
free survival (DFS). OS was calculated from the time of 
histopathological diagnosis to the time of death or last 
recorded event. DFS was calculated from the time of sur-
gical resection to the first evidence of recurrence or death 
from any cause. Life tables were used to calculate the 
survival rates and median survival time. The relationship 
between CD146 expression and clinicopathologic char-
acteristics was assessed using Pearson’s Chi-square test. 
Survival curves were obtained using the Kaplan–Meier 
method. Log-rank tests were used for statistical compari-
son of curves. Univariate and multivariate Cox regression 
methods were adapted to evaluate potential prognostic 
factors, yielding hazard ratios and 95 % confidence inter-
vals. P < 0.05 was considered statistically significant.
Results
Demographic characteristics
Table  1 summarizes the demographic characteris-
tics of the patients. The mean age was 48.3 years; the 
Table 1 Patients’ clinical and histopathological characteristics (n = 68)
TAH total abdominal hysterectomy, BSO bilateral salpingo-oophorectomy, OT omentectomy, PL pelvic lymphadenectomy, PLND para-aortic lymph node dissection
Characteristics No. case LMS (n = 36) ESS (n = 25) MMMT (n = 7)
Age (years)
 <50 38 (55.8 %) 20 17 1
 ≥50 30 (44.2 %) 16 8 6
Stage
 I 36 (53.9 %) 19 13 4
 II 3 (4.4 %) 3 0 0
 III 22 (32.4 %) 7 12 3
 IV 7 (10.3 %) 7 0 0
Tumor size (cm)
 <5 30 (44.1 %) 16 11 3
 ≥5 38 (55.9 %) 20 14 4
Pelvic lymphadenectomy
 Yes 34 (50 %) 17 13 4
 No 34 (50 %) 19 12 3
Lymph node metastasis
 Positive 24 (35.3 %) 18 4 2
 Negative 44 (64.7 %) 33 9 2
Surgical procedure
 TAH ± BSO/OT/PL/PLND 8 (11.8 %) 4 4 0
 TAH + BSO ±/PL/OT 29 (42.6 %) 17 12 0
 TAH + BSO + PL ± OT ± PLND 31 (45.6 %) 15 9 7
 Chemotherapy 22 (32.4 %) 13 9 0
 Radiotherapy 4 (5.9 %) 1 3 0
 Hormone therapy 1 (1.5 %) 0 1 0
 Chemotherapy and radiotherapy 20 (29.4 %) 10 3 7
 Chemotherapy and hormone therapy 3 (4.4 %) 1 2 0
 Radiotherapy and hormone therapy 1 (1.5 %) 0 1 0
 No adjuvant therapy 17 (25 %) 11 6 0
Distant metastasis and recurrence
 Pelvic 10 (14.7 %) 6 3 1
 Pelvic and liver/lung 6 (8.8 %) 4 2 0
 Lung 4 (5.9 %) 3 1 0
 Other parts 6 (8.8 %) 5 1 0
 None 42 (61.5 %) 18 18 6
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median age was 47.5  years (range 20–81  years). Pri-
mary symptoms included irregular menstrual bleed-
ing (19.2  %), postmenopausal or abnormal vaginal 
bleeding (30.8  %), pelvic mass (11.5  %), and abdomi-
nal pain (15.4  %). Twelve cases (17.6  %) were diag-
nosed incidentally. Of the 68 patients, 36 (52.9 %) had 
LMS, 25 (36.8  %) had malignant ESS, and 7 (10.3  %) 
had MMMT. Thirty-six cases (52.9  %) were stage I, 3 
(4.4 %) were stage II, 22 (32.4 %) were stage III, and 7 
(10.3 %) were stage IV.
All patients underwent surgery as initial treatment: 8 
(11.8 %) underwent TAH, 29 (42.6 %) TAH + BSO, and 
31 (45.6 %) TAH + BSO + PL. Fifty-one patients (75 %) 
received postoperative adjuvant therapy. Lymphovascular 
space invasion (LVSI) and lymph node metastasis were 
observed in 24 patients (35.3  %). Twenty-six patients 
(38.2  %) developed recurrence and 25 patients (36.8  %) 
died during follow-up.
CD146, P53, and Ki‑67 expression and their relationship 
with clinicopathologic characteristics of uterine sarcoma
On immunohistochemical analysis of the uterine sar-
coma tissue specimens, CD146-positive staining was 
localized not only in the epithelial compartment (the 
membrane and cytoplasm of tumor cells) but also in the 
vascular compartment. CD146 expression occurred more 
often in the vascular compartment. Forty-nine cases 
(72  %) exhibited vascular compartment CD146 expres-
sion, 35 of which were also positive for CD146 staining in 
the epithelial compartment (Fig. 1).
Fig. 1 Immunohistochemical staining for CD146, Ki‑67, and P53 expression in LMS, ESS, and MMMT. A CD146 mainly expressed in the epithelial 
compartment. B CD146 mainly expressed in the vascular epithelial compartment. C Nuclear Ki‑67 immunoreaction. D Nuclear P53 immunoreaction
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Overexpression of CD146 in the membrane and cyto-
plasm of tumor cells was observed in 8 (32 %) ESS cases, 
which was less than the 25 (69.4  %) cases observed in 
LMS and 2 (28.6 %) in MMMT. Positive nuclear P53 and 
Ki-67 immunoreactions were observed in 30 (44.1 %) and 
48 (70.6 %) cases, respectively. ESS patients had the low-
est positivity rates for both P53 and Ki-67 immunoreac-
tion, with P53 and Ki-67 expressed in seven (28 %) and 
six (24 %) cases, respectively (Table 2).
We analyzed the correlation between CD146 expres-
sion status and the clinicopathological characteristics 
of LMS; the results are summarized in Table  3. CD146 
overexpression on membrane and cytoplasm staining 
was closely related to lymph node metastasis (P = 0.021) 
and Ki-67 overexpression (P = 0.0053), but there was no 
significant correlation with age, tumor size, FIGO stage, 
or P53 overexpression.
Relationship between clinicopathologic parameters 
and survival
The median survival time was 30.7  months (range 
1–271 months). The 2- and 5-year OS rates were 57 and 
46  %, respectively; the 2- and 5-year DFS rates were 51 
and 44 %, respectively.
Even in more advanced-stage patients, the ESS group 
had better OS and DFS than the LMS group (Fig. 2A). 
The 2-year OS rate for ESS and LMS patients was 82 
and 66  %, respectively. The median OS for ESS and 
LMS patients was 136.5 and 61.02  months, respec-
tively (P = 0.024). The median DFS for ESS and LMS 
patients was 135.6 and 24.6  months, respectively 
(P = 0.037).
The median survival of patients with lymph node 
metastasis was 57  months compared with 136  months 
in lymph node-negative patients (P  <  0.05). Tumor 
size ≥5  cm was a significant adverse prognostic factor 
for LMS (P  =  0.02). The median survival of patients 
with tumor size <5 or ≥5 cm was 100 and 40 months, 
respectively. MI >10/HPF tended to be associated with 
an unfavorable outcome in LMS (P = 0.1). Multivariate 
analyses showed no statistical differences among these 
factors.
Adjuvant therapy had little impact on the management 
of uterine sarcoma, especially in early-stage disease. Post-
operative chemotherapy did not improve the survival 
time of stage I ESS patients (P = 0.42).
Prognostic significance of CD146, P53, and Ki‑67 
expression
CD146-positive LMS patients had a poorer prognosis 
than those who were CD146 negative. The 2-year OS 
rate was 53 % for CD146-positive patients and 84 % for 
CD146-negative patients (P = 0.0039, Fig. 2B). On multi-
variate analyses, CD146 positivity varied statistically sig-
nificantly with clinicopathological parameters, P53, and 
Ki-67 expression (P = 0.01).
Ki-67 overexpression was also related to an unfavorable 
outcome in LMS, with a significant difference observed 
(P = 0.0063, Fig. 2C). P53 overexpression in LMS showed 
no significant difference (P = 0.1).
In LMS patients with tumor size ≥5 cm, Kaplan–Meier 
estimates yielded a significant survival difference favoring 
CD146-positive patients (P = 0.0086, Fig. 2D).
CD146 positivity also tended to be associated with 
poor prognosis in ESS, though the difference was not 
significant (P = 0.1). Similarly, P53 and Ki-67 overexpres-
sion in ESS were related to poor prognosis but the differ-
ences were not significant (P = 0.1).
Table 2 Immunohistochemical analysis of uterine sarcoma 
specimens
ESS endometrial stromal sarcoma, LMS leiomyosarcoma, MMMT malignant 
mixed Müllerian tumor
a Cytoplasm and membrane staining
b Vascular endothelial cell staining
CD146a CD146b P53 Ki67
LMS 25/36 32/36 22/36 24/36
ESS 8/25 12/25 7/25 6/25
MMMT 2/7 5/7 1/7 4/7
Table 3 Correlation between  CD146 expression and  clin-
icopathologic features in LMS
LN lymph node
CD146 (−) CD146 (+) P value
Age
 <50 6 12 0.6
 ≥50 5 13
Stage
 I–II 7 11 0.4
 III–IV 4 14
Tumor size (cm)
 <5 14 8 0.16
 ≥5 12 17
LN statue
 Positive 2 15 0.021
 Negative 9 10
P53 expression
 Positive 7 15 0.68
 Negative 4 10
Ki67 expression
 Positive 4 20 0.0053
 Negative 8 5
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Discussion
Uterine sarcomas display aggressive clinical behavior 
and have a poor prognosis [3]. Our findings are in line 
with another study [17] in that the most common histo-
logic type of uterine sarcoma detected was LMS (52.9 %) 
whereas MMMT accounted for only 10.3 % of cases. The 
median survival time of the 68 patients was 30.7 months; 
the 5-year OS and DFS rates were 46 and 44 %, respec-
tively, which is consistent with a previous report in which 
OS and DFS were 45–47 and 34–36 %, respectively [17]. 
In a previous study, the outcome of ESS was significantly 
better than that of LMS and MMMT [18]. However, 
other studies have found, via multivariate analyses, that 
the histologic subtype does not affect survival. In our 
Fig. 2 Kaplan–Meier curves obtained from survival analyses (log‑rank) of patients with uterine sarcoma. A Histologic type was a significant prog‑
nostic factor for overall survival in LMS and ESS (P = 0.024). B CD146 showing significant correlation with overall survival in LMS. CD146‑positive 
patients had a poor prognosis compared with CD146‑negative patients (P = 0.0039). C Ki67 showing significant correlation with overall survival in 
LMS. Ki67‑positive patients had a poor prognosis compared with Ki67‑negative patients (P = 0.0063). D CD146 expression may be correlated with 
tumor size and poor prognosis in LMS (P = 0.026)
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study, ESS patients had a better prognosis than those 
with other histologic subtypes. Even in more advanced-
stage patients, the ESS group had better OS and DFS 
than the LMS group, with a 2-year survival rate of 82 %. 
A possible reason is that ESS tends to present as a less 
aggressive, early-stage disease with low levels of metas-
tasis [18].
Previous studies have found that stage, surgical treat-
ment, tumor grade, tumor size, and MI are prognostic 
factors for uterine sarcoma [19, 20]. Our results suggest 
that tumor size ≥5 cm, lymph node metastasis, and MI 
are significant prognostic factors in LMS. In our study, 38 
of 68 cases (55.9 %) of primary uterine sarcoma expressed 
CD146 in the epithelial compartment. In LMS, CD146 
expression in the epithelial compartment was associated 
with lymph node metastasis and was related to poor OS. 
Conversely, CD146 positivity in ESS patients did not cor-
relate with OS. CD146-positive LMS had a poorer prog-
nosis, the 2-year OS rate being 53 % compared with the 
2-year OS of 84 % in CD146-negative LMS (P = 0.0039). 
In LMS patients with tumor size ≥5 cm, the outcome was 
worse for those who were CD146 positive (P = 0.0086). 
Similar to other carcinomas, CD146 was overexpressed 
and associated with tumor metastasis and poor progno-
sis [11, 21]. Aldovini et  al. demonstrated that CD146 is 
involved in ovarian cancer and is a marker for poor prog-
nosis in this disease [21].
CD146 is a 113  kDa integral membrane glycopro-
tein, the amino acid sequence of which comprises a sig-
nal peptide, an extracellular fragment structure of five 
immunoglobulin-like domains (V-V-C2-C2-C2), a trans-
membrane region, and a short cytoplasmic tail [22]. It 
has been suggested that CD146 promotes tumor growth, 
angiogenesis, and metastasis [10]. CD146 plays a critical 
pro-migratory role in the vascular system, normal devel-
opment, and tumor progression patterning [23].
Interestingly, in the present study, CD146 was 
expressed in the vascular compartment in 49 cases, but 
also in the epithelial compartment in 38 cases. It has been 
established that LVSI is a significant prognostic factor in 
uterine sarcoma; LVSI and lymph node metastasis were 
shown to be relevant prognostic factors with an impact 
on OS and distant metastasis-free survival [24]. Moreo-
ver, on multivariate analysis, we found a significant rela-
tionship between CD146 overexpression and prognosis 
(P = 0.01). This implies that CD146 overexpression in the 
epithelial compartment may be related to angiogenesis 
and metastasis with a worse prognosis in LMS, and may 
serve as a potential LMS prognostic marker.
The prognosis of MMMT and UD may be related to 
CD146 expression in the vascular compartment. Due to 
the limited number of cases, we were unable to obtain 
significant statistical differences. The correlation between 
CD146 expression and clinicopathologic characteristics 
was not statistically significant.
CD146 positivity in the epithelial compartment showed 
a significant association with poor prognosis in ESS 
(P  =  0.1). Likewise, P53 and Ki-67 overexpression in 
LMS were related to an unfavorable outcome, though no 
significant difference was observed (P =  0.1). One pos-
sible reason may be a lack of test power, as the sample 
size was small, or it could have been due to the different 
mechanism of progression and metastasis in ESS.
Conclusions
CD146, P53, and Ki-67 were overexpressed in uterine 
sarcoma. CD146 expression in the epithelial compart-
ment was correlated with lymph node metastasis and 
was associated with poor OS in LMS, but had no impact 
on survival in ESS. CD146 may be a potential prognostic 
marker for LMS.
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